Pulmokine receives $1.5m Stage B VITA contract from NHLBI
Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.